Clinical trials: Still Disease
Epilepsy, Partial
Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam
This trial will evaluate the efficacy and safety of UCB44212 as add-on therapy in subjects with focal epilepsy.
- Trial name
- NCT00152503
- Testing
- Seletracetam (UCB44212)
- Where
- 17 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- UCB Pharma SA
Peripheral Nerve Block, Anxiety
Music vs Midazolam During Preop Nerve Block Placement - Part 2 Study On Anxiolytic Options Before Peripheral Nerve Blocks
This study is evaluating music vs midazolam as a means of anxiolysis for preoperative single-shot nerve block placement.
- Conditions
- Peripheral Nerve Block, Anxiety, Preoperative Anxiety
- Trial name
- NCT05610969
- Testing
- Music, Midazolam
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Pennsylvania
Multiple Myeloma
Preemptive Strike With Bortezomib in Multiple Myeloma Patients
To evaluate whether using the drug bortezomib at the start of remission will prevent relapse for a longer period of time.
- Trial name
- 2007-77 (NCT00657553)
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Arkansas
Arthritis, Juvenile Rheumatoid, Still's Disease, Juvenile Onset
Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis
The purpose of this study is to see if tocilizumab is safe and effective for treating systemic onset Juvenile Idiopathic Arthritis (soJIA).
- Trial name
- NCT00868751
- Testing
- tocilizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Tufts Medical Center
Systemic Juvenile Idiopathic Arthritis With Active Flare
Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
This two-part study assessed the sustained efficacy of canakinumab in the double-blind Part II and the ability to taper steroids in the open label Part I.
- Trial name
- β-SPECIFIC 2 (NCT00889863)
- Testing
- canakinumab
- Where
- 73 sites in United States, Argentina and 17 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Active Systemic, Onset Juvenile Idiopathic Arthritis
Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic Arthritis
This study has the following objectives: Primary objective: To determine the safety and tolerability of oral ITF2357 in patients with active SOJIA with inadequate response or intolerance to standard therapy with oral steroids and…
- Trial name
- SOJIA (NCT00570661)
- Testing
- ITF2357
- Where
- 5 sites in Romania, Serbia
- Volunteers
- 17 people
- Sponsor
- Italfarmaco
Systemic Juvenile Idiopathic Arthritis
Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)
This study assessed the initial efficacy and safety of canakinumab over a 4 week period in patients with systemic juvenile idiopathic arthritis (SJIA) having a flare.
- Trial name
- β-SPECIFIC 1 (NCT00886769)
- Testing
- Canakinumab
- Where
- 91 sites in United States, Argentina and 20 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Adult-Onset Still´s Disease
Canakinumab for Treatment of Adult-onset Still's Disease
The purpose of this trial is to investigate the efficacy of the treatment with canakinumab in participants with Adult-onset Still's Disease (AOSD) and active joint involvement.
- Trial name
- CONSIDER (NCT02204293)
- Testing
- Canakinumab
- Where
- 14 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Charite University, Berlin, Germany